(Boursier.com) — Inventive announces the drawing of the second tranche of 25 million euros as part of its financing contract with the European Investment Bank.
Inventiva will use the proceeds from this drawing to finance part of the ongoing pivotal Phase III clinical study evaluating lanifibranor in patients with NASH.
This second tranche comes with an interest rate of 7% per year, a maturity of 3 years and a final repayment which should take place after the expected publication of the results of the Phase III study, NATiV3 , evaluating lanifibranor in patients with NASH, expected in the first half of 2026.
These 25 million euros confirm Inventiva’s cash flow horizon estimated at the start of the third quarter of 2024.
©2024 Boursier.com